ABX196 not checked

Abivax S.A.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“ABX196 is a synthetic agonist of invariant Natural Killer T (iNKT) cells”In the company’s words, NCT03897543 on ClinicalTrials.gov
Tested for
Carcinoma, Hepatocellular
Main trialPhase 1/2
“Open-label, uncontrolled, Phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma”In the company’s words, NCT03897543 on ClinicalTrials.gov
Other names
Obefazimod

Other drugs for Carcinoma, Hepatocellular

All 130 drugs for Carcinoma, Hepatocellular

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Completed 14 Apr 2022 ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ABX196

Following is part of Solo: you see every change to ABX196 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in